Blockchain

Nubila Kickstarts Fundraising Round Led by IoTeX, VeChain and Other Leading Investors

San Francisco, United States, July 1st, 2024, Chainwire

 

Nubila, a leading data oracle specializing in accurate and actionable Environmental, Social, and Governance (ESG) data for the Decentralized Physical Infrastructure Network (DePIN) ecosystem, has kicked off its fundraising round. The on-going round is led by IoTeX and VeChain + Boston Consulting Group, with the participation from OrangeDAO, MH Ventures, Future Money Group, SNZ Capital, DePINsurf, Kronos Research, Taisu Ventures, Bytetrade, WaterDrip, Deepin Lab, Assembly Partners, Cyber, Radiance Ventures and Genopets, Nubila has raised $2.5 million to date.

This significant investment underscores the industry’s recognition of Nubila’s potential to leverage AI and tokenization to empower decision-making, drive sustainable development, and build financial products with ESG data.

“At Nubila, we are committed to building the infrastructure for the MachineFi revolution, serving as the ‘data sensor layer’ for our planet,” said Ben, the founder of Nubila. “Our vision is to create a comprehensive network of advanced weather stations and sensors that capture critical environmental data. Integrating real-time ESG data into an increasing number of AI models, such as Microsoft’s recently released Aurora atmospheric model, will enhance ESG assessments and drive more informed and sustainable decision-making across industries. With this funding, we are poised to scale our operations and expand our global reach, ensuring that we contribute significantly to the sustainability and well-being of our planet.”

The funds will be strategically used to scale Nubila’s operations, further develop its cutting-edge ESG Data Oracle, and pursue key strategic goals. These initiatives include enhancing data accuracy, expanding the network’s reach, increasing user engagement, and the awareness of sustainability investment.

“Nubila is at the forefront of leveraging DePIN and AI to transform ESG data management,” said Raullen Chai, Founder of IoTeX. “Their approach to creating a decentralized ESG network of community-owned IoT devices, delivering hyperlocal weather data to enhance predictions for various industries is revolutionary. By providing actionable environmental data, Nubila is not only enhancing ESG assessments but also enabling more informed and sustainable decision-making across various industries. We are excited to support their mission and look forward to seeing the significant impact they will make on the sustainability landscape.”

This network features advanced weather stations, the only ones equipped with high-precision sensors and cameras, dedicated to gathering detailed environmental data for accurate ESG assessments. To date, Nubila has deployed 16,000 stations worldwide, collectively capturing over 100TB in weather data.

About Nubila

Headquartered in San Francisco, Nubila is a pioneer in the Environmental, Social, and Governance (ESG) data sector, dedicated to transforming sustainability initiatives through innovative solutions. By building the largest ESG Data Oracle within the DePIN ecosystem, Nubila leverages AI and ESG tokenization to empower decision-making, drive sustainable development and build financial products.

 

Contact

Marketing Head
Darren Goh
Nubila
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

2024-10-02T11:08:00Z

PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

  • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
  • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
  • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

Keiretsu Forum: A Global Leader in Early-Stage Innovation

Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

"Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

Event Details

  • Date: October 31, 2024
  • Time: 8:00 AM – 6:00 PM EDT
  • Location: Convene City View, 30 S 17th St, Philadelphia, PA

Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

About Keiretsu Forum :

Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

About Dr. Martin Gershon

Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

For media inquiries, please contact:

Cindi Sutera
AMS Communications
[email protected]
610-613-2773


GlobeNewsWire News

Recent Comments